Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06999057 · ClinicalTrials.gov registry record · Early Phase 1
Quadriceps Motor Unit Adaptation to Simulated Knee Injury
A Early Phase 1 study, sponsored by University of Central Florida.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 45
- Enrollment target
NCT06999057: Recruiting Early Phase 1 study, sponsored by University of Central Florida.
NCT06999057 is a Early Phase 1 study that is actively recruiting participants, run by University of Central Florida. The registered enrollment target is 45 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (15% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06999057, a Early Phase 1 study, is actively recruiting participants, sponsored by University of Central Florida.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 45 participants
- Enrollment target
Study Summary
This study investigates how simulated knee injury-via artificial joint effusion or deafferentation-affects quadriceps motor unit behavior in healthy young adults. Participants will complete neuromuscular testing during a single 2-hour lab session. This research seeks to improve understanding of muscle inhibition and inform interventions after real-world knee trauma.
Primary Outcome
Measured via surface EMG decomposition
Interventions
- OTHER Sham injection
- DEVICE Joint Effusion via 60 mL Sterile Saline
- DRUG Intra-articular Lidocaine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2026-08-01 |
| Est. Completion | 2027-08-01 |
| Phase | Early Phase 1 |
What NCT06999057 shows while recruiting
NCT06999057 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (15% lower).
The record links to 0 conditions, and to 3 interventions - of which Sham injection is the first listed.
NCT06999057 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06999057 about?
NCT06999057 is a clinical study titled "Quadriceps Motor Unit Adaptation to Simulated Knee Injury". This study investigates how simulated knee injury-via artificial joint effusion or deafferentation-affects quadriceps motor unit behavior in healthy young adults. Participants will complete neuromuscular testing during a single 2-hour lab session. This research seeks to improve understanding of musc...
What is the current status of trial NCT06999057?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 45 participants. The study started on 2026-08-01. Estimated completion is 2027-08-01.
What interventions are being tested in trial NCT06999057?
The interventions under investigation include: Sham injection (OTHER), Joint Effusion via 60 mL Sterile Saline (DEVICE), Intra-articular Lidocaine (DRUG).
Who is sponsoring clinical trial NCT06999057?
This trial is sponsored by University of Central Florida, which has 91 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06999057's enrollment target sits among peer trials
45 575th of 2000 higher than 1,413 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI